BGAM
JAZZ icon

Boussard & Gavaudan Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Boussard & Gavaudan Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-2,680
Closed -$368K – 119
2014
Q1 		$368K Buy
+2,680
New +$403K 0.23% 13

Other funds holding JAZZ

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
LPC
Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
WBC
Westpac Banking Corp Sydney, Australia $1.44B AUM 28.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Boussard & Gavaudan Asset Management's JAZZ Position: Q2 2014 in Review

Boussard & Gavaudan Asset Management sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2014, closing a stake of 2,680 shares — an estimated $368K sold.

Boussard & Gavaudan Asset Management first reported a position in JAZZ in Q1 2014 and held it in 1 quarter. The position peaked at $368K in Q1 2014. 305 funds tracked by Wall St. Rank hold JAZZ as of Q2 2014.

  • Boussard & Gavaudan Asset Management reported no remaining Jazz Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Boussard & Gavaudan Asset Management sold 2,680 Jazz Pharmaceuticals shares in Q2 2014, an estimated $368K.
  • Boussard & Gavaudan Asset Management first reported a position in Jazz Pharmaceuticals in Q1 2014 and held it in 1 quarter.
  • Boussard & Gavaudan Asset Management's Jazz Pharmaceuticals position peaked at $368K in Q1 2014.
  • 305 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2014.

Based on Boussard & Gavaudan Asset Management's 13F filing for Q2 2014, filed 1 Aug 2014.